NL-OMON41586已完成3 期
A multicenter randomized phase III study to compare the combination trastuzumab and capecitabine, with or without pertuzumab, in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting (PHEREXA) - Pherexa
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Covance
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Disease-Specific:
- •1.Pathologically confirmed breast cancer and documented metastatic disease.
- •2.HER2-positive (FISH/CISH-positive or IHC 3+*) MBC confirmed by a Sponsor-designated central laboratory. Availability of a FFPE tumor tissue sample from primary tumor for eligibility testing (HER2-status) is mandatory (minimum 6 slides). Additional tumor tissue material for biomarker assessment is requested (if available).
- •3.Disease progression during or following a trastuzumab-based treatment for first-line metastatic breast cancer.
- •4.Trastuzumab must have been part of the last prior treatment regimen.
- •5.Prior treatment with a taxane-containing regimen.;General:
- •6.Female patients, age *18 years.
- •7.LVEF * 50% at baseline (assessed within 42 days prior to randomization) as determined by either 2D echocardiogram (ECHO) or MUGA (ECHO is the preferred method). If the patient is randomized, the same method of LVEF assessment, ECHO or MUGA, must be used throughout the study, and to the extent possible, be obtained at the same institution.
- •8.Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- •9.For women of childbearing potential agreement to use highly effective form of contraception (patient and/or partner, e.g., surgical sterilization, or true abstinence) or two effective forms of contraception, a reliable barrier method, condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and an intrauterine device (IUD) or intrauterine system (IUS) and to continue its use for the duration of study treatment and for at least 7 months after the last dose of study treatment. Periodic abstinence (e.g., calendar ovulation, symptothermal, post ovulation methods) and withdrawal are not acceptable methods of contraception. Postmenopausal is defined as * 12 months of amenorrhea.
- •10.Written and signed informed consent (approved by the Independent Ethics Committee) obtained prior to beginning any protocol-specific procedures.
排除标准
- •Cancer-Related:
- •1.Prior therapy with pertuzumab or capecitabine.
- •2.Concurrent immunotherapy or anticancer hormonal therapy.
- •3.Existing acute reversible effects of prior treatment. This generally means at least 3 weeks should have elapsed since prior chemotherapy and at least 4 weeks since prior (radical) radiotherapy or major surgery.
- •4.History of another malignancy which could affect compliance with the protocol or interpretation of results. Patients treated with curative intent and disease-free for at least 5 years are generally eligible, as are patients treated curatively for carcinoma in situ of the cervix or non melanomatous skin cancer.
- •5.CNS metastases which are not well controlled. Eligible patients must be asymptomatic, can not be receiving steroids, and must be enrolled at least 1 month after the end of the radiotherapy treatment. Note: CT or MRI scan of the brain is mandatory (within 4 weeks prior to randomization) in case of clinical suspicion of CNS metastases.
- •6.History of exposure to at least one of the following cumulative doses of anthracyclines:
- •*doxorubicin or liposomal doxorubicin > 360 mg/m2
- •*epirubicin > 720 mg/m2
- •*mitoxantrone > 120 mg/m2
- •*idarubicin > 90 mg/m2
- •*Other (e.g. liposomal doxorubicin or other anthracycline > the equivalent of 360 mg/m2 of doxorubicin)
- •*If more than 1 anthracycline has been used, then the cumulative dose must not exceed the equivalent of 360 mg/m2 of doxorubicin.
- •Hematological, Biochemical and Organ Function:
- •7.Current uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mmHg) or unstable angina.
- •8.History of CHF of any New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment (except for atrial fibrillation and/or paroxysmal supraventricular tachycardia).
- •9.History of myocardial infarction within 6 months of randomization.
- •10.History of LVEF decline to below 50% during or after prior trastuzumab therapy or other cardiac toxicity during previous trastuzumab treatment that necessitated discontinuation of trastuzumab.
- •11.Current dyspnoea at rest requiring supportive oxygen therapy or with significant pleural effusions.
- •General Exclusion Criteria
- •12.Inadequate organ function, evidenced by the following laboratory results within 28 days prior to randomization:
- •*absolute neutrophil count (ANC) < 1.5 x 109/L
- •*platelet count < 100 x 109/L
- •*hemoglobin < 9 g/dL
- •*serum (total) bilirubin > 1.5 x the upper limit of normal (ULN) (unless the patient has documented Gilbert*s syndrome)
- •*AST/SGOT or ALT/SGPT >2.5 x ULN (> 5 x ULN in patients with liver metastases)
- •*Alkaline phosphatase levels > 2.5 times the ULN at screening/baseline (> 5 x ULN in patients with liver metastases, or > 10 x ULN in patients with bone metastases)
- •*Moderate or severe renal impairment [creatinine clearance equal to or below 50ml/min (calculated according to Cockroft and Gault, see Appendix 2)], or serum creatinine > upper limit of normal (ULN)
- •*International normalized ratio (INR) and activated partial thromboplastin time (aPTT) >1.5 x ULN (unless on therapeutic coagulation)
- •13.Current severe, uncontrolled systemic disease (e.g. clinical significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; or bone fractures).
- •14.Evidence of any other disease, metabolic or psychological dysfunction, physical examination finding,
研究者
相似试验
进行中（未招募）
1 期
A multicenter randomized phase III study to compare capecitabine alone or in combination with trastuzumab in patients with HER2 positive metastatic breast cancer and progression after previous treatment with trastuzumab (Treatment Beyond Progression, TBP). - GBG26/TBPEUCTR2005-002084-85-GBGBG Forschungs GmbH482
进行中（未招募）
1 期
A study of a combination of Trastuzumab and Capecitabine with or without Pertuzumab in patients with HER2-positive metastatic breast cancerEUCTR2008-006801-17-CZF. Hoffmann-La Roche Ltd.450
进行中（未招募）
1 期
A study of a combination of Trastuzumab and Capecitabine with or without Pertuzumab in patients with HER2-positive metastatic breast cancerHER2 positive metastatic breast cancer which has progressed after one line of trastuzumab-based therapy in the metastatic settingMedDRA version: 20.0Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-006801-17-DEF. Hoffmann-La Roche Ltd.450
进行中（未招募）
不适用
A multicenter randomized phase III study to compare capecitabine alone or in combination with trastuzumab in patients with HER2 positive metastatic breast cancer and progression after previous treatment with trastuzumab (Treatment Beyond Progression) - GBG 26/TBPPatients with HER2 positive metastatic breast cancer and progression after previous treatment with trastuzumabMedDRA version: 7.1Level: LLTClassification code 10027475EUCTR2005-002084-85-DKGBG Forschungs GmbH482
进行中（未招募）
不适用
A multicenter randomized phase III study to compare capecitabine alone or in combination with trastuzumab in patients with HER2 positive metastatic breast cancer and progression after previous treatment with trastuzumab (Treatment Beyond Progression, TBP). - GBG26/TBPPatients with HER2 positive metastatic breast cancer and progression after previous treatment with trastuzumab.EUCTR2005-002084-85-SIGBG Forchungs GmBH482